For the first time, bacteriophage therapy treated a boy with chronic and antibiotic-resistant Achromobacter…
Steve Bryson, PhD
Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Steve Bryson, PhD
The Achromobacter bacteria species that is an increasing source of chronic lung infections in people with…
Elevated levels of fecal calprotectin protein, a biomarker for intestinal inflammation, was linked to worse gastrointestinal symptoms and…
People with cystic fibrosis (CF) are more frequently infected with oral Candida fungus and carry a higher number of…
The European Commission has approved Vertex’s…
Children with cystic fibrosis (CF) have an altered intestinal virome, or viral communities,…
Kalydeco treatment led to fewer deaths, transplants, hospitalizations, and exacerbations in people with cystic…
People with cystic fibrosis (CF) have higher levels of DNA from common microbes…
Problems with the CFTR protein in platelets, blood cells essential to clotting, activated these cells, both driving lung inflammation…
People with cystic fibrosis (CF) who were treated with Orkambi (lumacaftor/ivacaftor) have significantly less accumulation of fat…